株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:大鬱病性障害 (MDD) - 世界の医薬品の予測と市場分析

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

発行 GlobalData 商品コード 314723
出版日 ページ情報 英文 392 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.37円で換算しております。
Back to Top
PharmaPoint:大鬱病性障害 (MDD) - 世界の医薬品の予測と市場分析 PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025
出版日: 2016年10月05日 ページ情報: 英文 392 Pages
概要

大鬱病性障害 (MDD) は、世界で最も一般的な精神疾患の1つです。MDD市場は競争が激しく、30以上もの上市製品がMDD患者の治療に使用可能です。主力製品 (Eli LillyのCymbalta、大塚製薬/BMSのAbilify) の特許期間の満了、抗鬱薬の新製品 (Lundbeck/武田薬品工業のBrintellix) や将来有望な後期段階のパイプライン製品の導入を目前に、市場は大きく動いています。

当レポートでは、大鬱病性障害 (MDD) 治療薬市場について調査分析し、疾患の概要とガイドライン、競合情勢、主要薬剤の詳細情報 (製品説明、安全性、有効性) 、SWOT分析、売上高予測、影響分析 (動向、促進要因・抑制要因) などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 分類
  • 症状とサブタイプ
  • 予後
  • QOL

第4章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界の動向
  • 予測手法
    • 利用した情報源
    • 予測の前提条件と手法
    • 利用しなかった情報源
  • MDDの疫学予測
    • 12ヶ月の総患者数
    • 12ヶ月の総患者数 (年齢別)
    • 12ヶ月の総患者数 (性別)
    • 12ヶ月の総患者数 (年齢調整)
    • 12ヶ月の総患者数:重症度別
  • 議論
    • 疫学予測に関する考察
    • 分析の限界
    • 分析の強み

第5章 疾患の管理

  • 診断と治療の概要
  • 米国
  • EU5ヶ国
  • 日本

第6章 競合評価

  • 概要
  • 選択的セロトニン再取り込み阻害薬
  • セロトニン・ノルアドレナリン再取り込み阻害薬
  • 多様な抗鬱薬
  • その他の抗鬱薬
  • 抗精神病薬
  • その他の治療薬クラス

第7章 アンメットニーズと機会

  • 概要
  • 有効性のある新しい治療法
  • 安全性プロファイルの向上
  • 速やかな作用
  • 個別化治療のアプローチ
  • 患者の転帰予測の管理

第8章 パイプライン評価

  • 概要
  • 治験マッピング
  • 臨床開発中の有望な薬剤
  • 初期段階で開発中の有望な薬剤
  • その他の開発中の薬剤

第9章 現在・将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル

第10章 市場の見通し

  • 世界市場
  • 米国
  • EU5ヶ国
  • 日本

第11章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC126PIDR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly's Cymbalta and Otsuka/BMS' Abilify have occurred, and recent launches of Lundbeck/Takeda's Trintellix and Otsuka/Lundbeck's Rexulti will be a significant driver of growth in the 7MM.

It is estimated that pharmaceutical sales within the MDD market were approximately $3.2 Billion in 2015 across the 7MM. The US contributed 76.1% of these sales, generating an estimated $2.4 Billion. The large US share was predominantly due to sales from the atypical antipsychotics, such as Otsuka/BMS' Abilify and AstraZeneca's Seroquel XR, which have higher costs of therapy compared with other marketed antidepressants.

By the end of the forecast period in 2025, MDD sales in the 7MM are expected to grow to $5.8 Billion at a Compound Annual Growth Rate (CAGR) of 6.1% over the 10-year period. The majority of this growth is attributed to sales from the atypical antipsychotics, such as Otsuka/BMS' Abilify, AstraZeneca's Seroquel XR, and Otsuka/Lundbeck's Rexulti, which are expected to collectively capture 38.9% of the global market in 2025, and generate $2.2 Billion in sales.

According to Christos Michaelides, Analyst: “Atypical antipsychotics such as Otsuka/Bristol-Myers Squibb's Abilify, AstraZeneca's Seroquel XR, and Otsuka/Lundbeck's Rexulti ” are expected to collectively capture approximately 39% of the global market in 2025, and generate an impressive $2.2 Billion in sales. Although Abilify and Seroquel will experience some generic erosion over the forecast period, Rexulti will continue to drive sales upwards following its expected launches in the US and Europe in 2018.

The major drivers of growth of the MDD market during the forecast period include:

  • The growth of the atypical antipsychotics throughout the 7MM, most notably from Otsuka/Lundbeck's Rexulti.
  • The increasing global diagnosed prevalence of MDD, due to increased public awareness and routine screening for depressive disorders, as well as an increase in socioeconomic stress.
  • The potential introduction of six late-stage pipeline products into the MDD market, some of which have novel mechanisms of action (MOAs), such as Janssen's esketamine, Alkermes' ALKS-5461, and Allergan's rapastinel.

The report “PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 ” overview of MDD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

In particular, this report provides the following analysis:

  • Annualized MDD market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the MDD therapeutics market.
  • Pipeline analysis: focus on eight late-stage pipeline MDD drugs, discussing emerging trends as well as an overview of earlier phase drugs.
  • Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: AbbVie, Abbott Laboratories, Abbott Laboratories, Alkermes, Allergan, Asahi Kasei, Astellas, AstraZeneca, Avanir Pharmaceuticals, Axsome Therapeutics, Bristol-Myers Squibb, e-Therapeutics, Eli Lilly, GlaxoSmithKline, Gedeon Richter, Janssen, Lundbeck, Meiji Seika, Merck & Co., Methylation Sciences, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Mochida, Moksha8, Neuralstem Pharmaceuticals, Novartis, Otsuka, Pfizer, Pierre Fabre, Royalty Pharma, Sandoz, Shionogi, Takeda, Teva Pharmaceutical.

Table of Contents

1 Table of Contents 10

  • 1.1 List of Tables 15
  • 1.2 List of Figures 20

2 Introduction 22

  • 2.1 Related Reports 22
  • 2.2 Upcoming Related Reports 23

3 Disease Overview 24

  • 3.1 Etiology and Pathophysiology 24
    • 3.1.1 Etiology 24
    • 3.1.2 Pathophysiology 25
  • 3.2 Classification 28
  • 3.3 Symptoms and Subtypes of Major Depressive Disorder 30
  • 3.4 Prognosis 31
  • 3.5 Quality of Life 31

4 Epidemiology 32

  • 4.1 Disease Background 32
  • 4.2 Risk Factors and Comorbidities 33
  • 4.3 Global Trends 35
  • 4.4 Forecast Methodology 38
    • 4.4.1 Sources Used Tables 38
    • 4.4.2 Forecast Assumptions and Methods 40
    • 4.4.3 Sources Not Used 44
  • 4.5 Epidemiological Forecast for MDD (2015-2025) 46
    • 4.5.1 12-Month Total Prevalent Cases of MDD 46
    • 4.5.2 Age-Specific 12-Month Total Prevalent Cases of MDD 48
    • 4.5.3 Sex-Specific 12-Month Total Prevalent Cases of MDD 49
    • 4.5.4 Age-Standardized 12-Month Total Prevalence of MDD 51
    • 4.5.5 12-Month Total Prevalent Cases of MDD by Severity 52
  • 4.6 Discussion 53
    • 4.6.1 Epidemiological Forecast Insight 53
    • 4.6.2 Limitations of the Analysis 54
    • 4.6.3 Strengths of the Analysis 55

5 Disease Management 56

  • 5.1 Diagnosis and Treatment Overview 56
    • 5.1.1 Diagnosis 56
    • 5.1.2 Treatment Guidelines 57
    • 5.1.3 Clinical Practice 59
  • 5.2 US 63
  • 5.3 5EU 66
  • 5.4 Japan 70

6 Competitive Assessment 73

  • 6.1 Overview 73
  • 6.2 Selective Serotonin Reuptake Inhibitors 75
    • 6.2.1 Lexapro (Escitalopram) 75
    • 6.2.2 Viibryd (Vilazodone) 83
    • 6.2.3 Other Selective Serotonin Reuptake Inhibitors 87
  • 6.3 Serotonin-Norepinephrine Reuptake Inhibitors 101
    • 6.3.1 Cymbalta (Duloxetine) 101
    • 6.3.2 Effexor (Venlafaxine) 109
    • 6.3.3 Fetzima (Levomilnacipran) 116
    • 6.3.4 Savella (Milnacipran) 122
    • 6.3.5 Pristiq (Desvenlafaxine) 127
  • 6.4 Multimodal Antidepressants 132
    • 6.4.1 Trintellix (Vortioxetine) 132
  • 6.5 Other Antidepressants 141
    • 6.5.1 Bupropion 141
    • 6.5.2 Symbyax (Olanzapine/Fluoxetine) 147
    • 6.5.3 Mirtazapine 152
    • 6.5.4 Monoamine Oxidase Inhibitors 157
    • 6.5.5 Tricyclic Antidepressants 161
  • 6.6 Antipsychotics 165
    • 6.6.1 Abilify (Aripiprazole) 165
    • 6.6.2 Seroquel XR (Quetiapine XR) 172
    • 6.6.3 Rexulti (Brexpiprazole) 177
  • 6.7 Other Therapeutic Classes 183

7 Unmet Need and Opportunity 184

  • 7.1 Overview 184
  • 7.2 New Therapies with Better Efficacy 186
    • 7.2.1 Unmet Need 186
    • 7.2.2 Gap Analysis 188
    • 7.2.3 Opportunity 189
  • 7.3 Improved Safety Profiles 190
    • 7.3.1 Unmet Need 190
    • 7.3.2 Gap Analysis 192
    • 7.3.3 Opportunity 193
  • 7.4 Rapid Onset of Action 195
    • 7.4.1 Unmet Need 195
    • 7.4.2 Gap Analysis 196
    • 7.4.3 Opportunity 198
  • 7.5 Personalized Treatment Approach 199
    • 7.5.1 Unmet Need 199
    • 7.5.2 Gap Analysis 200
    • 7.5.3 Opportunity 201
  • 7.6 Manage Patient Outcome Expectations 203
    • 7.6.1 Unmet Need 203
    • 7.6.2 Gap Analysis 205
    • 7.6.3 Opportunity 206

8 Pipeline Assessment 208

  • 8.1 Overview 208
  • 8.2 Clinical Trial Mapping 208
    • 8.2.1 Clinical Trials by Class of Therapy 208
  • 8.3 Promising Drugs in Clinical Development 209
    • 8.3.1 ALKS-5461 213
    • 8.3.2 Vraylar (Cariprazine) 222
    • 8.3.3 ASC-01 229
    • 8.3.4 AXS-05 232
    • 8.3.5 Esketamine 239
    • 8.3.6 Rapastinel (GLYX-13) 247
    • 8.3.7 Strada (MSI-195) 255
    • 8.3.8 Viotra (Tramadol) 261
  • 8.4 Promising Drugs in Early-Stage Development 268
    • 8.4.1 CGP3466B 268
    • 8.4.2 NSI-189 269
  • 8.5 Other Drugs in Development 270

9 Current and Future Players 272

  • 9.1 Overview 272
  • 9.2 Trends in Corporate Strategy 274
  • 9.3 Company Profiles 275
    • 9.3.1 Allergan 275
    • 9.3.2 e-Therapeutics 278
    • 9.3.3 Alkermes 280
    • 9.3.4 Pfizer 282
    • 9.3.5 Otsuka 284
    • 9.3.6 Janssen 287
    • 9.3.7 Eli Lilly 290
    • 9.3.8 Lundbeck 292
    • 9.3.9 Takeda 295
    • 9.3.10 Axsome Therapeutics 297

10 Market Outlook 299

  • 10.1 Global Markets 299
    • 10.1.1 Forecast 299
    • 10.1.2 Drivers and Barriers - Global Issues 306
  • 10.2 US 306
    • 10.2.1 Forecast 306
    • 10.2.2 Key Events 309
    • 10.2.3 Drivers and Barriers 310
  • 10.3 5EU 310
    • 10.3.1 Forecast 310
    • 10.3.2 Key Events 315
    • 10.3.3 Drivers and Barriers 316
  • 10.4 Japan 318
    • 10.4.1 Forecast 318
    • 10.4.2 Key Events 320
    • 10.4.3 Drivers and Barriers 321

11 Appendix 322

  • 11.1 Bibliography 322
  • 11.2 Abbreviations 365
  • 11.3 Methodology 371
  • 11.4 Forecasting Methodology 371
    • 11.4.1 Diagnosed MDD Patients 371
    • 11.4.2 Percent Drug-Treated Patients 372
    • 11.4.3 Percent Treatment-Resistant Patients 372
    • 11.4.4 Drugs Included in Each Therapeutic Class 372
    • 11.4.5 Key Launch Dates and Patent Expiries 373
    • 11.4.6 General Pricing Assumptions 373
    • 11.4.7 Individual Drug Assumptions 374
    • 11.4.8 Generic Erosion 384
    • 11.4.9 Pricing of Pipeline Agents 385
  • 11.5 Primary Research - KOLs Interviewed for this Report 386
  • 11.6 Primary Research - High-Prescriber Survey 388
  • 11.7 About the Authors 389
    • 11.7.1 Analysts 389
    • 11.7.2 Therapy Area Director 389
    • 11.7.3 Epidemiologist 390
    • 11.7.4 Global Director of Therapy Analysis and Epidemiology 390
  • 11.8 About GlobalData 391
  • 11.9 Disclaimer 391

List of Tables

  • Table 1: Classification and Criteria of MDD (DSM-IV) and MDE (ICD-10) 29
  • Table 2: Subtypes of Major Depressive Disorder 30
  • Table 3: DSM-IV Diagnostic Criteria for MDD 33
  • Table 4: Risk Factors and Comorbidities for MDD 34
  • Table 5: Prevalence of the Most Frequent Psychiatric Comorbidities in Individuals With and Without MDD, Ages 18-64 Years 35
  • Table 6: 7MM, Total Prevalence (%) of MDD According to the DSM-IV Criteria, ≥18 Years 37
  • Table 7: 7MM, Total Prevalence (%) of MDD According to the DSM-III Criteria 37
  • Table 8: 7MM, Sources Used to Forecast the 12-Month Total Prevalence of MDD 39
  • Table 9: Sources Used to Forecast the 12-Month Total Prevalent Cases of MDD by Severity 40
  • Table 10: 7MM, Sources Not Used in Epidemiological Forecast for the 12-Month Total Prevalent Cases of MDD 45
  • Table 11: 7MM, 12-Month Total Prevalent Cases of MDD, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 47
  • Table 12: 7MM, 12-Month Total Prevalent Cases of MDD, by Age, Both Sexes, N (Row %), 2015 48
  • Table 13: 7MM, 12-Month Total Prevalent Cases of MDD, by Sex, Ages ≥18 Years, N (Row %), 2015 50
  • Table 14: Severity of Depressive Episodes According to ICD-10 and DSM-IV Diagnostic Criteria 57
  • Table 15: Treatment Guidelines for Major Depressive Disorder 58
  • Table 16: Most-Prescribed Drugs for MDD by Class in the 7MM, 2015 59
  • Table 17: Country Profile - US 66
  • Table 18: Country Profile - 5EU 69
  • Table 19: Country Profile - Japan 72
  • Table 20: Leading Treatments for MDD, 2016 75
  • Table 21: Product Profile - Lexapro 79
  • Table 22: Lexapro/Cipralex SWOT Analysis, 2016 82
  • Table 23: Product Profile - Viibryd 85
  • Table 24: Summary of Efficacy Results for the Primary Endpoint in Viibryd Clinical Trials 86
  • Table 25: Viibryd SWOT Analysis, 2016 87
  • Table 26: Summary of SSRIs, 2016 91
  • Table 27: SSRIs SWOT Analysis, 2016 101
  • Table 28: Product Profile - Cymbalta 106
  • Table 29: Cymbalta SWOT Analysis, 2016 108
  • Table 30: Product Profile - Effexor 113
  • Table 31: Effexor SWOT Analysis, 2016 115
  • Table 32: Product Profile - Fetzima 119
  • Table 33: Fetzima SWOT Analysis, 2016 121
  • Table 34: Product Profile - Savella 124
  • Table 35: Savella SWOT Analysis, 2016 126
  • Table 36: Product Profile - Pristiq 129
  • Table 37: Pristiq SWOT Analysis, 2016 131
  • Table 38: Product Profile - Trintellix 138
  • Table 39: Trintellix SWOT Analysis, 2016 140
  • Table 40: Product Profile - Bupropion 144
  • Table 41: Bupropion SWOT Analysis, 2016 146
  • Table 42: Product Profile - Symbyax 149
  • Table 43: Symbyax SWOT Analysis, 2016 151
  • Table 44: Product Profile - Mirtazapine 155
  • Table 45: Mirtazapine SWOT Analysis, 2016 157
  • Table 46: MAOIs SWOT Analysis, 2016 161
  • Table 47: TCAs SWOT Analysis, 2016 165
  • Table 48: Product Profile - Abilify 169
  • Table 49: Abilify SWOT Analysis, 2016 171
  • Table 50: Product Profile - Seroquel XR 174
  • Table 51: Seroquel XR SWOT Analysis, 2016 176
  • Table 52: Product Profile - Rexulti 180
  • Table 53: Rexulti SWOT Analysis, 2016 182
  • Table 54: Summary of Minor Therapeutic Classes in MDD, 2016 183
  • Table 55: Unmet Needs and Opportunities in MDD 185
  • Table 56: Promising Drugs in Clinical Development for MDD, 2016 210
  • Table 57: Comparison of Drugs in Development for MDD, 2016 212
  • Table 58: Product Profile - ALKS-5461 217
  • Table 59: SWOT Analysis - ALKS-5461, 2016 221
  • Table 60: Product Profile - Vraylar 225
  • Table 61: SWOT Analysis - Vraylar, 2016 228
  • Table 62: Product Profile - ASC-01 230
  • Table 63: SWOT Analysis - ASC-01, 2016 232
  • Table 64: Product Profile - AXS-05 236
  • Table 65: SWOT Analysis - AXS-05, 2016 238
  • Table 66: Product Profile - Esketamine 243
  • Table 67: SWOT Analysis - Esketamine, 2016 246
  • Table 68: Product Profile - Rapastinel 251
  • Table 69: SWOT Analysis - Rapastinel, 2016 254
  • Table 70: Product Profile - Strada 259
  • Table 71: SWOT Analysis - Strada, 2016 261
  • Table 72: Product Profile - Viotra 264
  • Table 73: SWOT Analysis - Viotra, 2015 267
  • Table 74: Drugs in Development, 2016 271
  • Table 75: Key Companies in the MDD Market in the 7MM 273
  • Table 76: Allergan's MDD Portfolio Assessment, 2016 277
  • Table 77: Allergan SWOT Analysis in MDD, 2015-2025 278
  • Table 78: e-Therapeutics' MDD Portfolio Assessment, 2016 279
  • Table 79: e-Therapeutics SWOT Analysis in MDD, 2015-2025 280
  • Table 80: Alkermes' MDD Portfolio Assessment, 2016 282
  • Table 81: Alkermes SWOT Analysis in MDD, 2015-2025 282
  • Table 82: Pfizer's MDD Portfolio Assessment, 2016 283
  • Table 83: Pfizer SWOT Analysis in MDD, 2015-2025 284
  • Table 84: Otsuka's MDD Portfolio Assessment, 2016 286
  • Table 85: Otsuka SWOT Analysis in MDD, 2015-2025 287
  • Table 86: Janssen's MDD Portfolio Assessment, 2016 289
  • Table 87: Janssen SWOT Analysis in MDD, 2015-2025 290
  • Table 88: Eli Lilly's MDD Portfolio Assessment, 2016 291
  • Table 89: Eli Lilly SWOT Analysis in MDD, 2015-2025 292
  • Table 90: Lundbeck's MDD Portfolio Assessment, 2016 294
  • Table 91: Lundbeck SWOT Analysis in MDD, 2015-2025 295
  • Table 92: Takeda's MDD Portfolio Assessment, 2016 296
  • Table 93: Takeda SWOT Analysis in MDD, 2015-2025 296
  • Table 94: Axsome Therapeutics' MDD Portfolio Assessment, 2016 298
  • Table 95: Axsome Therapeutics SWOT Analysis in MDD, 2015-2025 298
  • Table 96: MDD Market - Drivers and Barriers, 2015-2025 306
  • Table 97: Key Events Impacting Sales for MDD Therapies in the US, 2015-2025 309
  • Table 98: MDD Market - Drivers and Barriers in the US, 2015-2025 310
  • Table 99: Key Events Impacting Sales for MDD Therapies in the 5EU, 2015-2025 315
  • Table 100: MDD Market - Drivers and Barriers in the 5EU, 2015-2025 316
  • Table 101: National Healthcare Authorities and Governmental Drug Pricing Authorities in the 5EU 317
  • Table 102: Key Events Impacting Sales for MDD Therapies in Japan, 2015-2025 320
  • Table 103: MDD Market - Drivers and Barriers in Japan, 2015-2025 321
  • Table 104: Key Launch Dates 373
  • Table 105: Key Patent Expiries 373
  • Table 106: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 388

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons 28
  • Figure 2: 7MM, 12-Month Total Prevalent Cases of MDD, Ages ≥18 Years, Both Sexes, N, 2015-2025 47
  • Figure 3: 7MM, 12-Month Total Prevalent Cases of MDD, by Age, Both Sexes, N, 2015 49
  • Figure 4: 7MM, 12-Month Total Prevalent Cases of MDD, by Sex, Ages ≥18 Years, N, 2015 51
  • Figure 5: 7MM, Age-Standardized 12-Month Total Prevalence (%) of MDD, by Sex, Ages ≥18 Years, 2015 52
  • Figure 6: 7MM, 12-Month Total Prevalent Cases of MDD by Severity, Both Sexes, Ages ≥18 Years, 2015 53
  • Figure 7: Disease Management Model for Major Depressive Disorder 60
  • Figure 8: Major Depressive Disorder Treatment Algorithm 62
  • Figure 9: MDD Therapeutics - Phase II and III Clinical Trials in the 7MM, 2016 209
  • Figure 10: MDD Phase II/Phase III Pipeline, 2016 211
  • Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2015-2025 213
  • Figure 12: Clinical and Commercial Positioning of ALKS-5461 220
  • Figure 13: Clinical and Commercial Positioning of Vraylar 227
  • Figure 14: Clinical and Commercial Positioning of ASC-01 231
  • Figure 15: Clinical and Commercial Positioning of AXS-05 237
  • Figure 16: Clinical and Commercial Positioning of Esketamine 245
  • Figure 17: Clinical and Commercial Positioning of Rapastinel 253
  • Figure 18: Clinical and Commercial Positioning of Strada 260
  • Figure 19: Clinical and Commercial Positioning of Viotra 266
  • Figure 20: Company Portfolio Gap Analysis in MDD, 2015-2025 274
  • Figure 21: Global Sales by Region for MDD Therapies, 2015 and 2025 302
  • Figure 22: Global Sales by Region for MDD Therapies, 2015-2025 303
  • Figure 23: Global Sales by Drug Class for MDD Therapies, 2015 and 2025 304
  • Figure 24: Global Sales by Drug Class for MDD Therapies, 2015-2025 305
  • Figure 25: US Sales by Drug Class for MDD Therapies, 2015 and 2025 308
  • Figure 26: US Sales by Drug Class for MDD Therapies, 2015-2025 309
  • Figure 27: 5EU Sales by Drug Class for MDD Therapies, 2015 and 2025 312
  • Figure 28: 5EU Sales by Drug Class for MDD Therapies, 2015-2025 313
  • Figure 29: 5EU Sales by Region for MDD Therapies, 2015 and 2025 314
  • Figure 30: Japan Sales by Drug Class for MDD Therapies, 2015 and 2025 319
  • Figure 31: Japan Sales by Drug Class for MDD Therapies, 2015-2025 320
Back to Top